Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BL1332 ophthalmic solution
BL1332 · 1 trial · 1 indication
To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
| Arm | Type | Description |
|---|---|---|
| BL1332 ophthalmic solution (0.06%, 0.15%, and 0.30% concentrations) | EXPERIMENTAL | BL1332 ophthalmic solution (0.06%, 0.15%, and 0.30% concentrations) administered as topical ocular drops |
| BL1332 vehicle | PLACEBO_COMPARATOR | BL1332 vehicle administered as topical ocular drops |
| Name | Type | Description |
|---|---|---|
| BL1332 ophthalmic solution | DRUG | Both arms taken four times a day for 1 day |
| BL1332 ophthalmic vehicle | DRUG | Both arms taken four times a day for 1 day |
Inclusion Criteria: 1. Written informed consent prior to conduct of any study-related assessment 2. Male and female subjects ≥18 to ≤50 years of age and in good health, as assessed by the Investigator from past medical history, physical examination, and laboratory tests at Screening 3. Vital signs ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |
BL1332 is an investigational small molecule being developed for the treatment of ocular pain. It is formulated as an ophthalmic solution for topical administration to the eye. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BL1332 targets the TRPV1 ion channel, a protein involved in pain signaling. By modulating this channel, the drug is intended to address ocular pain. TRPV1 is a well-known target in pain research, and BL1332 is designed to act on it locally in the eye.
BL1332 is being developed by Bausch + Lomb Corporation, a company traded on the stock exchange under the ticker BLCO. The company is conducting clinical trials to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers.
BL1332 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of ascending concentrations of the ophthalmic solution in healthy volunteers.
BL1332 is being studied in a Phase 1 clinical trial registered as NCT06978244. This randomized, double-blind, placebo-controlled study is evaluating the safety, tolerability, and pharmacokinetics of ascending concentrations of topical ocular BL1332 in healthy volunteers. The trial is active but not recruiting participants and is being conducted in the United States.